Rationale and Design of the Cessation Of Pharmacotherapy In Recovered Chemotherapy-induced cardioToxicity (COP-RCT): A Pilot Study

Cancer therapeutics-related cardiac dysfunction (CTRCD) is a well-recognised complication of cancer treatment. Treatment of CTRCD involves cardioprotective therapy (CPT) which can lead to a recovery of CTRCD with normalisation of the left ventricular ejection fraction (LVEF). As a result, there are potentially millions of cancer survivors with recovered CTRCD on CPT. Cardioprotective therapy can be associated with an undesirable long-term pill burden, financial costs, and side effects. Cancer survivorship is anticipated to increase significantly by the end of this decade.

https://www.heartlungcirc.org/article/S1443-9506(23)04368-8/fulltext?rss=yes

Source: Heart, Lung and Circulation - November 8, 2023 Category: Cardiology Authors: Christopher Yu, Tomoko Negishi, Faraz Pathan, Aaron Sverdlov, Liza Thomas, Mitra Shirazi, Chieh Yang Koo, Li Ling Tan, Sakiko Miyazaki, Kazuaki Negishi Tags: Original Article Source Type: research